890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Panitumumab Neoplasm	Astellas Pharma Inc	P2	BBB (73)
Relatlimab Neoplasm	Bristol-Myers Squibb	P2	BB (68)
Vitamin D Neoplasm	Tanta University	P4	BB (68)
Pralsetinib, Trans- Neoplasm	Seoul National University Bundang Hospital	P3	BB (67)
Dexasone Neoplasm	Hellenic Society of Hematology	P3	BB (66)
Irinotecan Neoplasm	Mirati Therapeutics Inc.	P4	BB (66)
Nivestim Neoplasm	Ankara Etlik City Hospital	P2	BB (66)
Carboplatin Neoplasm	Bristol-Myers Squibb	P3	BB (64)
Metformin Neoplasm	M.D. Anderson Cancer Center	P2	BB (64)
Cetuximab Neoplasm	Mirati Therapeutics Inc.	P4	B (63)
Lomustine Neoplasm	Telix Pharmaceuticals (Innovations) Pty Limited	P3	B (63)
Ribociclib Neoplasm	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P4	B (63)
(+)-Vincristine Neoplasm	Pfizer	P4	B (63)
Adriamycin Neoplasm	The First Affiliated Hospital of Soochow University	P3	B (62)
Atezolizumab Neoplasm	Hoffmann-La Roche	P2/3	B (62)
Nogitecan Neoplasm	Actuate Therapeutics Inc.	P3	B (62)
Prednisone Neoplasm	The First Affiliated Hospital of Soochow University	P3	B (62)
Bortezomib Neoplasm	Hellenic Society of Hematology	P3	B (61)
Cediranib Neoplasm	AstraZeneca	P2	B (61)
Durvalumab Neoplasm	GlaxoSmithKline	P4	B (61)
Fludarabine Neoplasm	National Cancer Institute (NCI)	P2	B (61)
Letrozole Neoplasm	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	B (61)
Resiquimod Neoplasm	Eikon Therapeutics	P2	B (61)
Rivoceranib Neoplasm	Beidahuang Industry Group General Hospital	P3	B (61)
25-HYDROXYCALCIFEROL Neoplasm	University of Ilorin Teaching Hospital	P3	B (60)
Alectinib Neoplasm	Cancer Research UK	P3	B (60)
arx788 Neoplasm	Ambrx, Inc.	P2	B (60)
Carfilzomib Neoplasm	Fondazione EMN Italy Onlus	P3	B (60)
Cyclophosphamide Neoplasm	National Cancer Institute (NCI)	P3	B (60)
Cytarabine Neoplasm	Kura Oncology, Inc.	P1/2	B (60)
Denosumab Neoplasm	Alliance for Clinical Trials in Oncology	P4	B (60)
Esmolol Neoplasm	Consorcio Centro de Investigación Biomédica en Red (CIBER)	P3	B (60)
Etoposide Neoplasm	Shanghai Pulmonary Hospital, Shanghai, China	P2	B (60)
Famitinib Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
Favezelimab Neoplasm	Merck Sharp & Dohme LLC	P3	B (60)
Fulvestrant Neoplasm	Terremoto Biosciences Inc.	P2/3	B (60)
Gm-Csf Neoplasm	Second Affiliated Hospital of Soochow University	P2	B (60)
Ipilimumab Neoplasm	Partner Therapeutics, Inc.	P2	B (60)
Itraconazole Neoplasm	Boehringer Ingelheim	P1	B (60)
Lenalidomide Neoplasm	Hellenic Society of Hematology	P3	B (60)
Lenvatinib Neoplasm	Tongji Hospital	P3	B (60)
Mesna Neoplasm	M.D. Anderson Cancer Center	P2	B (60)
Nab-Sirolimus Neoplasm	Aadi Bioscience, Inc.	P2	B (60)
Nivolumab Neoplasm	Boehringer Ingelheim	P2	B (60)
Osimertinib Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P3	B (60)
Palbociclib Neoplasm	Tianjin Medical University Second Hospital	P2	B (60)
Panobinostat Neoplasm	National Cancer Institute (NCI)	P3	B (60)
Pertuzumab Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P3	B (60)
pf-08634404 Neoplasm	Pfizer	P3	B (60)
Ponatinib Neoplasm	Fondazione per la Medicina Personalizzata	P2	B (60)

Showing 1 to 50 of 890 assets

PreviousPage 1 of 18Next